Albumin-based Drug Delivery Using Cysteine 34 Chemical Conjugates–Important Considerations and Requirements

References

• Andersen JT Dalhus B Cameron J et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun.3, 610 (2012).
   PubMed Web of Science ®Google Scholar
• Chaudhury C Mehnaz S Robinson JM et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med.197 (3), 315–322 (2003).
   PubMed Web of Science ®Google Scholar
• Sleep D Cameron J Evans LR . Albumin as a versatile platform for drug delivery platform for drug half-life extension. Biochim. Biophys. Acta1830 (12), 5526–5534 (2013).
   PubMed Web of Science ®Google Scholar
• Liu Z Chen X . Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev.45 (5), 1432–1456 (2016).
   PubMed Web of Science ®Google Scholar
• Sleep D . Albumin and its application in drug delivery. Expert Opin. Drug Deliv.12 (5), 793–812 (2015).
   PubMed Web of Science ®Google Scholar
• Andersen JT Dalhus B Viuff D et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J. Biol. Chem.289 (19) 13492–13502 (2014).
   PubMed Web of Science ®Google Scholar
• Miyamura S Imafuku T Anraku M et al. Comparison of posttranslational modification and the functional impairment of human serum albumin in commercial preparations. J. Pharm. Sci.105 (3), 1043–1049 (2015).
   Web of Science ®Google Scholar
• Ishima Y Akaike T Krag-Hansen U et al. S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding. J. Biol. Chem.283 (50) 34966–34975 (2008).
   PubMed Web of Science ®Google Scholar
• Frahm GE Smith DGS Kane A et al. Determination of supplier-to-supplier and lot-to-lot variability in glycation of recombianant human serum albumin expressed in Oryza sativa. PLoS ONE9 (10), e109893 (2014).
   PubMed Web of Science ®Google Scholar
• Peters T . Serum-albumin. Adv. Protein Chem.37, 161–245 (1985).
   PubMedGoogle Scholar
• Sugi S Kashima A Mochizuki S Noda M Kobayashi K . Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng.12 (6), 439–446 (1999).
   PubMedGoogle Scholar
• Stewart AJ Blindauer CA Berezenko S Sleep D Tooth D Sadler PJ . Role of Tyr84 in controlling the reactivity of Cys34 of human albumin. FEBS J.272, 353–362 (2005).
   PubMed Web of Science ®Google Scholar
• Anraku M Chuang VTG Maruyama T Otagiri M . Redox properties of serum albumin. Biochim. Biophys. Acta1830, 5465–5472 (2013).
   PubMed Web of Science ®Google Scholar
• Torres MJ Turell L Botti H et al. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic derivative by fatty acids. Arch. Biochem. Biophys.521, 102–110 (2012).
   PubMed Web of Science ®Google Scholar
• Paulech J Solis N Cordwell SJ . Characterization of reaction conditions providing rapid and specific cysteine alkylation for peptide-based mass spectrometry. BBA Proteins Proteom.1834, 372–379 (2013).
   PubMed Web of Science ®Google Scholar
• Galvani M Hamdan M Herbert B Righetti PG . Alkylation kinetics of proteins in preparation for two-dimensional maps: a matrix assisted laser desorption/ionization-mass spectrometry investigation. Electrophoresis22, 2058–2065 (2001).
   PubMed Web of Science ®Google Scholar
• Rogers LK Leinweber BL Smith CV . Detection of reversible protein thiol modifications in tissues. Anal. Biochem.358, 171–184 (2006).
   PubMed Web of Science ®Google Scholar
• Regazzoni L Colombo S Mazzolari A Vistoli G Carini M . Serum albumin as a probe for testing the selectivity of irreversible cysteine protease inhibitors: the case of vinyl sulfones. J. Pharm. Biomed. Anal.124, 294–302 (2016).
   PubMed Web of Science ®Google Scholar
• Kratz F . A clinical update of using albumin as a drug vehicle–a commentary. J. Control. Rel.190, 331–336 (2014).
   PubMed Web of Science ®Google Scholar
• Shen BQ Xu K Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol.30, 184–189 (2012).
   PubMed Web of Science ®Google Scholar
• Smith MEB Caspersen MB Robinson E et al. A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine. Org. Biomol. Chem.3, 7946–7949 (2015).
   Google Scholar
• Bernardim B Cal PMSD Matos MJ et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat. Commun.7, 13128 (2016).
   PubMed Web of Science ®Google Scholar
• Kim J Bronson CL Hayton WL et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. Gastrolintest. Liver Physiol.290 (2), G352–G360 (2006).
   PubMed Web of Science ®Google Scholar
• Sand KMK Bern M Nilsen J et al. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). J. Biol. Chem.289, 34583–34594 (2014).
   PubMed Web of Science ®Google Scholar
• Petersen SS Kläning E Ebbesen MF et al. Neonatal Fc receptor binding tolerance toward the covalent conjugation of payloads to cysteine 34 of human albumin variants. Mol. Pharm.13, 677–682 (2016).
   PubMedGoogle Scholar
• Schm⊘kel JS Voldum A Tsakiridou G et al. Site-selective conjugation of an anti-coagulant aptamer to recombinant albumins towards maintained neonatal Fc receptor binding. Nanotechnology28 (20), 204004 (2017).
   PubMed Web of Science ®Google Scholar
• Sand KMK Bern M Nilsen J Noordzij NT Sandlie I Andersen JT . Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol.5, 682 (2015).
   PubMed Web of Science ®Google Scholar
• Andersen JT Cameron J Plumridge A Evans L Sleep D Sandlie I . Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusions therapeutics. J. Biol. Chem.288, 24277–24285 (2013).
   PubMed Web of Science ®Google Scholar
• Andersen JT Daba MB Berntzen G Michaelsen TE Sandlie I . Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem.285, 4826–4836 (2010).
   PubMed Web of Science ®Google Scholar
• Evans L Hughes M Waters J et al. The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. Purif.73, 113–124 (2010).
   PubMed Web of Science ®Google Scholar
• Proetzel G Roopenian DC . Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods65, 48–153 (2014).
   Web of Science ®Google Scholar
• Roopenian DC Low BE Christianson GJ Proetzel G Sproule TJ Wiles MV . Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. mAbs7 (2), 344–351 (2015).
   PubMed Web of Science ®Google Scholar
• Viuff D Antunes F Evans LR et al. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. J. Control. Rel.223, 22–30 (2016).
   PubMed Web of Science ®Google Scholar
• Peng Y Deng L Ding Y et al. Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation. PLoS ONE9 (2), e89932 (2014).
   PubMed Web of Science ®Google Scholar
• Edwards W Fung-Leung W-P Huang C et al. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life. J. Biol. Chem.289 (33), 22704–22714 (2014).
   PubMed Web of Science ®Google Scholar
• Huang Y-S Wen X-f Y Z-Y Wu Y-L Lu Y Zhou L-F . Development and characterization of a novel fusion protein of a mutated granulocyte colony-stimulating factor and human serum albumin in Pichia pastoris. PLoS ONE9 (12), e115840 (2014).
   PubMed Web of Science ®Google Scholar
• Liu M Huang Y Hu L et al. Selective delivery of interleukin-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol.12, 68 (2012).
   PubMed Web of Science ®Google Scholar
• Simon M Frey R Zangemeister-Wittke U Plückthun A . Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjug. Chem.24, 1955–1966 (2013).
   PubMed Web of Science ®Google Scholar
• Lim SI Hahn YS Kwon I . Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. J. Control. Rel.207, 93–100 (2015).
   PubMed Web of Science ®Google Scholar
• Ehrlich GK Michel H Truitt T et al. Preparation and characterization of albumin conjugates of a truncated peptide YY analog for half-life extension. Bioconjug. Chem.24 (12), 2015–2024 (2013).
   PubMed Web of Science ®Google Scholar
• Baggio LL Huang Q Cao X Drucker DJ . An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murin energy and glucose homeostasis. Gastroenterology134 (4) 1137–1147 (2008).
   PubMed Web of Science ®Google Scholar
• Ikuta S Chuan VTG Ishima Y et al. Albumin fusion of thioredoxin–the production and evaluation of its biological activity for potential therapeutic applications. J. Control. Rel.147, 17–23 (2010).
   PubMed Web of Science ®Google Scholar
• Müller N Schneider B Pfizenmaier K Wajant K . Superior serum half life of albumin tagged TNF ligand. Biochem. Bioph. Res. Commun.396, 793–799 (2010).
   PubMed Web of Science ®Google Scholar
• Li L Guo Q Liu J et al. Recombinant HAS-CMG2 is a promising anthrax toxin inhibitor. Toxins8 (1), 28 (2016).
   PubMed Web of Science ®Google Scholar
• Yang B Lim SI Kim JC Tae G Kwon I . Site-specific albumination as an alternative to PEGylation for the enhanced serum half-life in vivo. Biomacromolecules17 (5), 1811–1817 (2016).
   PubMed Web of Science ®Google Scholar
• Metzner HJ Weimer T Kronthaler U Lang W Schulte S . Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb. Haemost.102 (4), 634–44 (2009).
   PubMed Web of Science ®Google Scholar
• Nolte MW Nichols TC Mueller-Cohrs J et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and haemophilia B dogs. J. Thromb. Haemost.10 (8), 1591–1599 (2012).
   PubMed Web of Science ®Google Scholar
• Santagostino E . PROLONG-9FP clinical development program–Phase I results of recombinant fusion protein linking coagulation factor IX with recombiantn albumin (rIX-FP). Thromb. Res.131 (Suppl. 2), S7–S10 (2013).
   PubMedGoogle Scholar
• Harris S Gilhooly L McEwan A et al. Albumin and albumin variants: pharmacokinetics and biodistribution studies in mice. Presented at : AAPS National Biotechnology. MA, USA, 16–18 May 2016.
   Google Scholar
• McEwen A Harris S Henson C Wood S . Albumin and albumin-drug conjugates: pharmacokinetics and tissue distribution studies. Presented at : AAPS National Biotechnology. CA, USA, 19–21 May 2014.
   Google Scholar
• Wagner JD Cann JA Zhang L Harwood HJ . Diabetes and obesity research using nonhuman primates. In : Nonhuman Primates in Biomedical Research.AbeeCRMansfieldKTardifSDMorrisT ( Ed.). Academic Press, CA, USA, 703 (2012).
   Google Scholar
• Peters T . All About Albumin: Biochemistry, Genetics and Medical Applications.Chapter 5–Metabolism: Albumin in the body. Academic Press, CA, USA, 10 (1996). www.sciencedirect.com/science/book/9780125521109
   Google Scholar